THE EFFECT OF DOXORUBICIN-INDUCED OXIDATIVE STRESS ON RESISTANCE OF INTESTINAL MUCOSA

Authors:

Abstract:

The paper presents the findings of our own studies on the evaluation of the effect of anthracycline-induced oxidative stress on the level of N-acetylneuraminic acid and the state of the processes of free radical oxidation and antioxidant protection in the mucous membrane of rat small and large intestines depending on the presence of nonalcoholic steatohepatitis. 30 mature outbred albino rats were involved into studies. The cumulative dose of doxorubicin was 15 mg/kg. In the mucous membrane of the small intestine of rats with nonalcoholic steatohepatitis, administration of doxorubicin resulted in less pronounced oxidative damage and 1.2-fold decrease in N-acetylneuraminic acid concentration compared to rats without nonalcoholic steatohepatitis. It has been proved that administration of doxorubicin led to the development of doxorubicin-induced oxidative stress in the intestinal mucosa of rats with more severe lesions of the small intestine, regardless of the presence of nonalcoholic steatohepatitis.

Keywords:

doxorubicin oxidative stress lipid peroxidation antioxidant system mucosal resistance intestine

References:

1. Kamishnikov VS. Сlinicheskaya biokhimiya. Minsk: Belarus; 2000; 2: 463. [in Russian]
2. Korolyuk MA, Ivanova LI, Mayorova IG, Tokarev VE. Metod opredeleniya aktivnosti katalazy. Laboratornoye delo. 1988; 1:16–9. [in Russian]
3. Skrypnyk IM, Maslova GS. Tsytoprotektorni ta protykyslotni zasoby v kompleksnomu likuvanni erozyvno-vyrazkovykh urazhen hastroduodenalnoyi zony u khvorykh na leikemiyu. Novosti meditsiny і farmatsii. 2012; 2: 24–26. [in Ukrainian]
4. Stalnaya ID, Garishvili TG. Metod opredeleniya malonovogo dialdegida s pomoshchyu tiobarbiturovoy kisloty. Sovremennye metody v biokhimii. Moskva: Meditsina; 1977; 66-68 s. [in Russian]
5. Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013 Aug; 88(8):642–6.
6. Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020 05 20; 152:116–41.
7. Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst. 2013 Dec 18; 105(24):1862–70.
8. Kuzu M, Kandemir FM, Yildirim S, Kucukler S, Caglayan C, Turk E. Morin attenuates doxorubicin-induced heart and brain damage by reducing oxidative stress, inflammation and apoptosis. Biomed Pharmacother. 2018 Oct; 106:443–53.
9. Lennon H, Sperrin M, Badrick E, Renehan AG. The Obesity paradox in cancer: a review. Curr Oncol Rep. 2016 09; 18(9):56.
10. Martin J, Howard SC, Pillai A, Vogel P, Naren AP, Davis S, et al. The weaned pig as a model for Doxorubicin-induced mucositis. Chemotherapy. 2014; 60(1):24–36.
11. Navarro WH, Loberiza FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):541–51.
12. Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, et al. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods. 2013 Jun; 23(5):337–45.
13. Schlesinger S, Siegert S, Koch M, Walter J, Heits N, Hinz S, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis. Cancer Causes Control. 2014 Oct; 25(10):1407–18.
14. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013 Apr 15; 119(8):1528–36.
15. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013 Feb; 65(2):157–70.

Publication:

«World of Medicine and Biology» Vol. 17 No. 75 (2021) , с. 221-224
УДК 616.341/.345:616.89

DOI:

https://doi.org/10.26724/2079-8334-2021-1-75-221-224